I agree totally with this summary of the presentation.
I also now doubt that our BOD have the competence to commercialise the technology. I do not mean that as a criticism of the individuals on the board. They have done a fantastic job in developing the technology but a different kind of beast is needed for a commercialisation program.
I did think there was one point in the presentation when TK gave a "nudge, nudge, wink, wink" to the shareholders to continue to hold strong (at around 12.17 minutes). It is like he has been told to parrot a particular line but clearly doesn't agree with it personally.
Also, interesting to me is the casual comments about past and on-going discussions with other parties.
What still galls me is that, if the independent expert, values a successful confirmatory trial of the COVID test at 13.1c/share, why the offer is not made at that upper level. It demonstrates to me that Pfizer is calling all the shots in this "deal". Borne out by what TK said at the beginning of the presentation that Pfizer wanted the "deal" to proceed by way of a scheme and it sounds like RAP didn't have a say in that decision.
- Forums
- ASX - By Stock
- RAP
- Ann: Investor Webinar
Ann: Investor Webinar, page-57
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online